NYSE:NAVB Navidea Biopharmaceuticals (NAVB) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free NAVB Stock Alerts $0.04 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.04▼$0.0450-Day Range$0.03▼$0.0552-Week Range$0.02▼$0.28Volume6,635 shsAverage Volume105,871 shsMarket Capitalization$3.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Navidea Biopharmaceuticals alerts: Email Address Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About Navidea Biopharmaceuticals Stock (NYSE:NAVB)Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.Read More NAVB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NAVB Stock News HeadlinesApril 21, 2024 | americanbankingnews.comNavidea Biopharmaceuticals (NYSE:NAVB) Now Covered by Analysts at StockNews.comFebruary 23, 2024 | benzinga.comNavidea Biopharmaceutical Stock (OTC:NAVB), Short Interest ReportApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… February 22, 2024 | benzinga.comNavidea Biopharmaceutical Stock (OTC:NAVB) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comNavidea Biopharmaceutical Stock (OTC:NAVB) Insider TradesJanuary 29, 2024 | bizjournals.comCentral Ohio public company voluntarily deregisters stockJanuary 26, 2024 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting ObligationsJanuary 26, 2024 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting ObligationsApril 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.January 11, 2024 | investing.comSuzhou Zelgen Biopharmaceuticals Co Ltd (688266)December 1, 2023 | msn.comNavidea settles litigation with Capital Royalty, stock rallies 30%December 1, 2023 | markets.businessinsider.comNavidea Biopharmaceuticals, CRG Settle All Ongoing LitigationNovember 1, 2023 | morningstar.comNavidea Biopharmaceuticals Inc NAVBOctober 26, 2023 | investing.comNavidea Biopharmaceuticals faces delisting from NYSE American, plans to move to OTC marketsOctober 6, 2023 | bizjournals.comNYSE American halts trading on Navidea stock after delisting recommendedOctober 5, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common StockOctober 5, 2023 | tmcnet.comNYSE American to Suspend Trading in Navidea Biopharmaceuticals, Inc. (NAVB)August 10, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing PanelAugust 1, 2023 | finance.yahoo.comNYSE American starts to delist Navidea stock, company to appealJuly 31, 2023 | benzinga.comWhy Navidea Biopharmaceuticals Shares Are NosedivingJuly 31, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Presses Ahead, Embraces OpportunitiesJuly 28, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American DeterminationJuly 28, 2023 | businesswire.comNYSE American to Commence Delisting Proceedings Against Navidea Biopharmaceuticals, Inc. (NAVB)July 28, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial OfficerJuly 13, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps DownJuly 6, 2023 | bizjournals.comDublin biotech proposes reverse stock split, stock-for-debt swapJune 30, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain AssetsSee More Headlines Receive NAVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNYSE:NAVB CUSIPN/A CIK810509 Webwww.navidea.com Phone614-793-7500Fax614-793-7522Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,180,000.00 Net MarginsN/A Pretax Margin-860,700.00% Return on EquityN/A Return on Assets-166.65% Debt Debt-to-Equity RatioN/A Current Ratio0.56 Quick Ratio0.51 Sales & Book Value Annual Sales$70,000.00 Price / Sales52.61 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-0.15Miscellaneous Outstanding Shares100,080,000Free Float56,367,000Market Cap$3.68 million OptionableNo Data Beta1.13 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Craig A. Dais CPA (Age 58)CFO & Principal Accounting Officer Dr. Michael Sherman Blue F.A.C.E.P.M.D., Chief Medical OfficerKey CompetitorsMyMD PharmaceuticalsNASDAQ:MYMDVirax Biolabs GroupNASDAQ:VRAXBiomericaNASDAQ:BMRAGeoVax LabsNASDAQ:GOVXPhaseBio PharmaceuticalsNASDAQ:PHASView All Competitors NAVB Stock Analysis - Frequently Asked Questions How have NAVB shares performed in 2024? Navidea Biopharmaceuticals' stock was trading at $0.0552 at the beginning of 2024. Since then, NAVB shares have decreased by 33.3% and is now trading at $0.0368. View the best growth stocks for 2024 here. When is Navidea Biopharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our NAVB earnings forecast. How were Navidea Biopharmaceuticals' earnings last quarter? Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. The firm had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.60 million. How do I buy shares of Navidea Biopharmaceuticals? Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NAVB) was last updated on 4/25/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryNew Trump BombshellThe Freeport Society1970’s computer coder issues shocking A.I. warningTradeSmithNew York goes dark, then America.Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
